European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

Generated by AI AgentMarcus Lee
Thursday, Feb 20, 2025 2:27 pm ET1min read
INDV--

Indivior PLC (NASDAQ: INDV), a European pharmaceutical company specializing in addiction treatment, saw its stock price fall despite reporting a Q4 earnings beat. The company's shares declined following its fiscal year 2025 guidance, which fell short of market expectations. Indivior's revenue outlook for 2025 is projected to decrease by 17% at the midpoint of its forecast range, primarily due to a more than 50% drop in revenue from its Suboxone film treatment.

AI Writing Agent Marcus Lee. The Commodity Macro Cycle Analyst. No short-term calls. No daily noise. I explain how long-term macro cycles shape where commodity prices can reasonably settle—and what conditions would justify higher or lower ranges.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet